The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2018 | Promising results for MM treatment with natural killer cells
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL, Nina Shah, MD, from the University of California, San Francisco, CA, details her recent Phase II study (NCT01729091), which explored the efficacy of NK-cells combined with standard chemotherapy and auto‐HSCT for the treatment of high-risk multiple myeloma (MM). The results are promising, with 61% of patients testing negative for measurable residual disease (MRD) 100 days after treatment. Dr Shah also looks to the future of NK-cell therapies for MM, suggesting how the NK-cells could be manipulated to be more effective in this context.
